Article citationsMore>>

V. Diehl, J. Franklin, D. Hasenclever, H. Tesch, M. Pfreundschuh, B. Lathan, et al., “BEACOPP, a New Dose-Escalated and Accelerated Regimen, Is at Least as Effective as COPP/ABVD in Patients with Advanced-Stage Hodgkin’s Lymphoma: Interim Report from a Trial of the German Hodgkin’s Lymphoma Study Group,” Journal of Clinical Oncology, Vol. 16, No. 12, 1998, pp. 3810-3821.

has been cited by the following article:

• TITLE: Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancer—A Single Institution Experience

  AUTHORS: Ofer Purim, Yulia Kundel, Roni Shapira, Baruch Brenner

  KEYWORDS: Gastric Cancer; Dose-Dense; Cisplatin; Fluorouracil

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.2, April 15, 2013

  ABSTRACT: Chemotherapy with continuous infusion of 5-fluorouracil and cisplatin in a monthly schedule is one of the most common regimens in the treatment of advanced gastric cancer. In this study, we evaluated the efficacy and safety of a dosedense administration of this regimen in this patient population. Sixty-six consecutive patients with previously untreated histologically confirmed unresectable or metastatic gastric adenocarcinoma were treated with a 2-hour infusion of cisplatin 100 mg/m2 followed by continuous infusion of 5-fluorouracil 1000 mg/m2/day for 5 days, every 21 days. The most common grade ≥3 toxicities were fatigue (42%), nausea/vomiting (30%) and leucopenia (12%). Four patients (6%) died from treatment-related toxicity. The response rate was 35%, the median progression-free survival was 4.3 months and the median survival was 5.9 months. In light of these results, the dose-dense approach seems to offer little, if any, benefit compared with the standard regimens.